Literature DB >> 15851920

Estimates of HIV incidence among persons testing for HIV using the sensitive/less sensitive enzyme immunoassy, New York City, 2001.

Denis Nash1, Yussef Bennani, Chitra Ramaswamy, Lucia Torian.   

Abstract

BACKGROUND: Estimates of the incidence of HIV infection among persons testing for HIV can be derived by applying a newly available serologic test to the diagnostic specimen of HIV-positive persons. Such estimates would enhance the targeting of HIV prevention resources and provide a sensitive outcome measure for prevention program evaluation. The goal of this investigation was to estimate the incidence of HIV infection among persons testing for HIV in New York City.
METHODS: The study population consisted of persons testing for HIV in public settings in New York City during 2001 (n = 114,703). We applied a less sensitive enzyme immunoassay (LS-EIA) (Vironostika, BioMerieux, Durham, NC) to the diagnostic blood specimen of 1022 persons in whom HIV (non-AIDS) had been diagnosed for the first time in 2001. The distribution of transmission risk among HIV-negative persons--men who have sex with men (MSM), injection drug users (IDUs), heterosexuals-from a large telephone health survey was used to generate denominators for transmission risk groups.
RESULTS: The 1022 persons tested by the LS-EIA represented 27% of all persons in whom HIV (non-AIDS) had been diagnosed in New York City during 2001. The incidence of HIV was estimated to be 0.29% per year (95% CI: 0.20-0.38), and was significantly higher for men than women (rate ratio 3.6, 95% CI: 2.6-5.1), and HIV incidence increased with age. Male IDU and MSM testers had the highest HIV incidence rates: 2.7% per year (95% CI: 2.3-3.1) and 2.5% per year (95% CI: 2.1-2.8), respectively.
CONCLUSIONS: Male IDUs and MSM may be good candidates for intensified targeting of HIV prevention resources in New York City.

Entities:  

Mesh:

Year:  2005        PMID: 15851920     DOI: 10.1097/01.qai.0000144446.52141.4c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

Review 1.  Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States.

Authors:  Scott S Santibanez; Richard S Garfein; Andrea Swartzendruber; David W Purcell; Lynn A Paxton; Alan E Greenberg
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

2.  Interpopulation variation in HIV testing promptness may introduce bias in HIV incidence estimates using the serologic testing algorithm for recent HIV seroconversion.

Authors:  Edward White; Gary Goldbaum; Steven Goodreau; Thomas Lumley; Stephen E Hawes
Journal:  Sex Transm Infect       Date:  2010-06-24       Impact factor: 3.519

3.  Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years--New York City, 2002.

Authors:  Susan E Manning; Lorna E Thorpe; Chitra Ramaswamy; Anjum Hajat; Melissa A Marx; Adam M Karpati; Farzad Mostashari; Melissa R Pfeiffer; Denis Nash
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

Review 4.  Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries.

Authors:  Ron Stall; Luis Duran; Stephen R Wisniewski; Mark S Friedman; Michael P Marshal; Willi McFarland; Thomas E Guadamuz; Thomas C Mills
Journal:  AIDS Behav       Date:  2009-02-10

5.  Use of a rapid HIV home test to screen sexual partners: an evaluation of its possible use and relative risk.

Authors:  Ana Ventuneac; Alex Carballo-Diéguez; Cheng-Shiun Leu; Bruce Levin; Jose Bauermeister; Emily Woodman-Maynard; Rebecca Giguere
Journal:  AIDS Behav       Date:  2009-05-05

Review 6.  HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis.

Authors:  Ethan Gough; Mirjam C Kempf; Laura Graham; Marvin Manzanero; Edward W Hook; Al Bartolucci; Eric Chamot
Journal:  BMC Public Health       Date:  2010-12-21       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.